Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease

ISSN:
1365-2036
Source:
Blackwell Publishing Journal Backfiles 1879-2005
Topics:
Medicine
Notes:
Background : Crohn's disease is associated with low bone mineral density and altered bone metabolism.Aim : To assess the evolution of bone metabolism in Crohn's disease patients treated with infliximab.Methods : We studied 71 Crohn's disease patients treated for the first time with infliximab for refractory Crohn's disease. Biochemical markers of bone formation (type-I procollagen N-terminal propeptide, bone-specific alkaline phosphatase, osteocalcin) and of bone resorption (C-telopeptide of type-I collagen) were measured in the serum before and 8 weeks after infliximab therapy and compared with values in a matched healthy control group.Results : Eight weeks after treatment with infliximab, a normalization of bone markers was observed with a median increase in formation markers of 14–51% according to marker and a lower but significant decrease in resorption marker (median 11%). A clinically relevant increase in bone formation markers was present in 30–61% of patients according to the marker. A clinically relevant decrease in C-telopeptide of type-I collagen was present in 38% of patients. No association was found with any tested demographic or clinical parameter.Conclusion : Infliximab therapy in Crohn's disease may rapidly influence bone metabolism by acting either on bone formation or bone resorption. This improvement seems to be independent of clinical response to infliximab.
Type of Medium:
Electronic Resource
URL:
_version_ 1798290073813254145
autor Franchimont, N.
Putzeys, V.
Collette, J.
Vermeire, S.
Rutgeerts, P.
De Vos, M.
Van Gossum, A.
Franchimont, D.
Fiasse, R.
Pelckmans, P.
Malaise, M.
Belaiche, J.
Louis, E.
autorsonst Franchimont, N.
Putzeys, V.
Collette, J.
Vermeire, S.
Rutgeerts, P.
De Vos, M.
Van Gossum, A.
Franchimont, D.
Fiasse, R.
Pelckmans, P.
Malaise, M.
Belaiche, J.
Louis, E.
book_url http://dx.doi.org/10.1111/j.1365-2036.2004.02152.x
datenlieferant nat_lic_papers
hauptsatz hsatz_simple
identnr NLZ242197256
insertion_date 2012-04-27
issn 1365-2036
journal_name Alimentary pharmacology & therapeutics
materialart 1
notes Background : Crohn's disease is associated with low bone mineral density and altered bone metabolism.Aim : To assess the evolution of bone metabolism in Crohn's disease patients treated with infliximab.Methods : We studied 71 Crohn's disease patients treated for the first time with infliximab for refractory Crohn's disease. Biochemical markers of bone formation (type-I procollagen N-terminal propeptide, bone-specific alkaline phosphatase, osteocalcin) and of bone resorption (C-telopeptide of type-I collagen) were measured in the serum before and 8 weeks after infliximab therapy and compared with values in a matched healthy control group.Results : Eight weeks after treatment with infliximab, a normalization of bone markers was observed with a median increase in formation markers of 14–51% according to marker and a lower but significant decrease in resorption marker (median 11%). A clinically relevant increase in bone formation markers was present in 30–61% of patients according to the marker. A clinically relevant decrease in C-telopeptide of type-I collagen was present in 38% of patients. No association was found with any tested demographic or clinical parameter.Conclusion : Infliximab therapy in Crohn's disease may rapidly influence bone metabolism by acting either on bone formation or bone resorption. This improvement seems to be independent of clinical response to infliximab.
package_name Blackwell Publishing
publikationsjahr_anzeige 2004
publikationsjahr_facette 2004
publikationsjahr_intervall 7999:2000-2004
publikationsjahr_sort 2004
publikationsort Oxford, UK
publisher Blackwell Science Ltd
reference 20 (2004), S. 0
search_space articles
shingle_author_1 Franchimont, N.
Putzeys, V.
Collette, J.
Vermeire, S.
Rutgeerts, P.
De Vos, M.
Van Gossum, A.
Franchimont, D.
Fiasse, R.
Pelckmans, P.
Malaise, M.
Belaiche, J.
Louis, E.
shingle_author_2 Franchimont, N.
Putzeys, V.
Collette, J.
Vermeire, S.
Rutgeerts, P.
De Vos, M.
Van Gossum, A.
Franchimont, D.
Fiasse, R.
Pelckmans, P.
Malaise, M.
Belaiche, J.
Louis, E.
shingle_author_3 Franchimont, N.
Putzeys, V.
Collette, J.
Vermeire, S.
Rutgeerts, P.
De Vos, M.
Van Gossum, A.
Franchimont, D.
Fiasse, R.
Pelckmans, P.
Malaise, M.
Belaiche, J.
Louis, E.
shingle_author_4 Franchimont, N.
Putzeys, V.
Collette, J.
Vermeire, S.
Rutgeerts, P.
De Vos, M.
Van Gossum, A.
Franchimont, D.
Fiasse, R.
Pelckmans, P.
Malaise, M.
Belaiche, J.
Louis, E.
shingle_catch_all_1 Franchimont, N.
Putzeys, V.
Collette, J.
Vermeire, S.
Rutgeerts, P.
De Vos, M.
Van Gossum, A.
Franchimont, D.
Fiasse, R.
Pelckmans, P.
Malaise, M.
Belaiche, J.
Louis, E.
Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease
Blackwell Science Ltd
Background : Crohn's disease is associated with low bone mineral density and altered bone metabolism.Aim : To assess the evolution of bone metabolism in Crohn's disease patients treated with infliximab.Methods : We studied 71 Crohn's disease patients treated for the first time with infliximab for refractory Crohn's disease. Biochemical markers of bone formation (type-I procollagen N-terminal propeptide, bone-specific alkaline phosphatase, osteocalcin) and of bone resorption (C-telopeptide of type-I collagen) were measured in the serum before and 8 weeks after infliximab therapy and compared with values in a matched healthy control group.Results : Eight weeks after treatment with infliximab, a normalization of bone markers was observed with a median increase in formation markers of 14–51% according to marker and a lower but significant decrease in resorption marker (median 11%). A clinically relevant increase in bone formation markers was present in 30–61% of patients according to the marker. A clinically relevant decrease in C-telopeptide of type-I collagen was present in 38% of patients. No association was found with any tested demographic or clinical parameter.Conclusion : Infliximab therapy in Crohn's disease may rapidly influence bone metabolism by acting either on bone formation or bone resorption. This improvement seems to be independent of clinical response to infliximab.
1365-2036
13652036
shingle_catch_all_2 Franchimont, N.
Putzeys, V.
Collette, J.
Vermeire, S.
Rutgeerts, P.
De Vos, M.
Van Gossum, A.
Franchimont, D.
Fiasse, R.
Pelckmans, P.
Malaise, M.
Belaiche, J.
Louis, E.
Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease
Blackwell Science Ltd
Background : Crohn's disease is associated with low bone mineral density and altered bone metabolism.Aim : To assess the evolution of bone metabolism in Crohn's disease patients treated with infliximab.Methods : We studied 71 Crohn's disease patients treated for the first time with infliximab for refractory Crohn's disease. Biochemical markers of bone formation (type-I procollagen N-terminal propeptide, bone-specific alkaline phosphatase, osteocalcin) and of bone resorption (C-telopeptide of type-I collagen) were measured in the serum before and 8 weeks after infliximab therapy and compared with values in a matched healthy control group.Results : Eight weeks after treatment with infliximab, a normalization of bone markers was observed with a median increase in formation markers of 14–51% according to marker and a lower but significant decrease in resorption marker (median 11%). A clinically relevant increase in bone formation markers was present in 30–61% of patients according to the marker. A clinically relevant decrease in C-telopeptide of type-I collagen was present in 38% of patients. No association was found with any tested demographic or clinical parameter.Conclusion : Infliximab therapy in Crohn's disease may rapidly influence bone metabolism by acting either on bone formation or bone resorption. This improvement seems to be independent of clinical response to infliximab.
1365-2036
13652036
shingle_catch_all_3 Franchimont, N.
Putzeys, V.
Collette, J.
Vermeire, S.
Rutgeerts, P.
De Vos, M.
Van Gossum, A.
Franchimont, D.
Fiasse, R.
Pelckmans, P.
Malaise, M.
Belaiche, J.
Louis, E.
Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease
Blackwell Science Ltd
Background : Crohn's disease is associated with low bone mineral density and altered bone metabolism.Aim : To assess the evolution of bone metabolism in Crohn's disease patients treated with infliximab.Methods : We studied 71 Crohn's disease patients treated for the first time with infliximab for refractory Crohn's disease. Biochemical markers of bone formation (type-I procollagen N-terminal propeptide, bone-specific alkaline phosphatase, osteocalcin) and of bone resorption (C-telopeptide of type-I collagen) were measured in the serum before and 8 weeks after infliximab therapy and compared with values in a matched healthy control group.Results : Eight weeks after treatment with infliximab, a normalization of bone markers was observed with a median increase in formation markers of 14–51% according to marker and a lower but significant decrease in resorption marker (median 11%). A clinically relevant increase in bone formation markers was present in 30–61% of patients according to the marker. A clinically relevant decrease in C-telopeptide of type-I collagen was present in 38% of patients. No association was found with any tested demographic or clinical parameter.Conclusion : Infliximab therapy in Crohn's disease may rapidly influence bone metabolism by acting either on bone formation or bone resorption. This improvement seems to be independent of clinical response to infliximab.
1365-2036
13652036
shingle_catch_all_4 Franchimont, N.
Putzeys, V.
Collette, J.
Vermeire, S.
Rutgeerts, P.
De Vos, M.
Van Gossum, A.
Franchimont, D.
Fiasse, R.
Pelckmans, P.
Malaise, M.
Belaiche, J.
Louis, E.
Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease
Blackwell Science Ltd
Background : Crohn's disease is associated with low bone mineral density and altered bone metabolism.Aim : To assess the evolution of bone metabolism in Crohn's disease patients treated with infliximab.Methods : We studied 71 Crohn's disease patients treated for the first time with infliximab for refractory Crohn's disease. Biochemical markers of bone formation (type-I procollagen N-terminal propeptide, bone-specific alkaline phosphatase, osteocalcin) and of bone resorption (C-telopeptide of type-I collagen) were measured in the serum before and 8 weeks after infliximab therapy and compared with values in a matched healthy control group.Results : Eight weeks after treatment with infliximab, a normalization of bone markers was observed with a median increase in formation markers of 14–51% according to marker and a lower but significant decrease in resorption marker (median 11%). A clinically relevant increase in bone formation markers was present in 30–61% of patients according to the marker. A clinically relevant decrease in C-telopeptide of type-I collagen was present in 38% of patients. No association was found with any tested demographic or clinical parameter.Conclusion : Infliximab therapy in Crohn's disease may rapidly influence bone metabolism by acting either on bone formation or bone resorption. This improvement seems to be independent of clinical response to infliximab.
1365-2036
13652036
shingle_title_1 Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease
shingle_title_2 Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease
shingle_title_3 Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease
shingle_title_4 Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease
sigel_instance_filter dkfz
geomar
wilbert
ipn
albert
source_archive Blackwell Publishing Journal Backfiles 1879-2005
timestamp 2024-05-06T08:10:56.559Z
titel Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease
titel_suche Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease
topic WW-YZ
uid nat_lic_papers_NLZ242197256